Roche Reports the P-III (RHONE-X) Study Data of Vabysmo for the Treatment of Diabetic Macular Edema (DME)
Shots:
- The P-III (RHONE-X) study is a 2yrs. extension trial assessing the safety & tolerability of Vabysmo (according to a personalized treatment interval) to treat DME in patients (n=1,474) from the P-III (YOSEMITE & RHINE) trials receiving either Vabysmo or aflibercept (2mg)
- Individuals sustained the improved visions & drying of retinal fluid with ~80% of individuals expanding their treatment to Q3M TO Q4M after 4yrs. in the exploratory analysis
- Moreover, over 90% of Vabysmo-treated patients attained the absence of DME, with central subfield thickness below 325 microns in a pre-specified exploratory endpoint. Safety profile aligned with Vabysmo’s known safety
Ref: Roche | Image: Roche
Related News:- Roche’s Vabysmo Prefilled Syringe Receives the US FDA’s Approval for Vision Loss
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
